Merck KGaA Stock
€131.70
Your prediction
Merck KGaA Stock
Pros and Cons of Merck KGaA in the next few years
Pros
Cons
Performance of Merck KGaA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Merck KGaA | 0.110% | -5.052% | 12.196% | 15.042% | 7.563% | -20.801% | -12.736% |
| Bayer AG | 4.600% | 1.443% | -4.931% | 30.900% | -3.055% | -31.552% | -32.796% |
| Biogen Inc. | 3.190% | -2.342% | 1.482% | 48.571% | 12.432% | -38.059% | -48.335% |
| BioMarin Pharmaceutical Inc. | 0.690% | -5.323% | 6.480% | -2.424% | -6.699% | -46.022% | -30.914% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Merck (US Symbol: MKGAF) operates within the dynamic pharmaceutical industry, and its financial performance reflects a blend of growth potential and certain challenges. With a solid market capitalization of approximately €72.1 billion and a range of strategic investments, Merck exhibits an underlying strength capable of sustaining its operations and exploring future growth avenues. Analyzing the financials provides a deeper understanding of both the strengths and weaknesses that shape the company's market position.
Strong Revenue Generation
Merck's total revenue for the most recent year stands at approximately €20.82 billion. This solid revenue base underscores the company's ability to generate substantial cash flow, crucial for funding operational activities, research and development (R&D), and other strategic initiatives.
Solid Profit Margins
The profit margin is reported at 13.07%, indicating that Merck is successful in converting a significant portion of its sales into net income. This efficiency is essential in maintaining a competitive edge within an industry characterized by high research and development costs.
Comments
News
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
Key Points
- Interested in CG Oncology, Inc.? Here are five stocks we like better.
- CG Oncology said its lead bladder cancer therapy, cretostimogene, has shown encouraging efficacy in
Merck: Navigating the Patent Cliff and Future Growth Prospects
Explore the exciting world of Merck (NYSE: MRK) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends
ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs
Key Points
- Interested in ALX Oncology Holdings Inc.? Here are five stocks we like better.
- ALX Oncology expects key data readouts in the coming months for its lead CD47 drug evorpacept and its